HOME › DRUGS › INSULIN LISPRO
ACTIVE SUBSTANCE / INN

INSULIN LISPRO

Brand name(s): Insulin lispro Sanofi, ADMELOG SOLOSTAR, Humalog, Bysumlog, Liprolog, ADMELOG, Lyumjev (previously Liumjev)
FDA LISTED
EMA LISTED
PRESCRIPTION
WITHDRAWN
AUTHORISED
BLA209196
Diabetes Mellitus
ACTIVE SUBSTANCE
Insulin Lispro
REGULATORS
FDA · EMA
SPONSORS / MAH
Gan & Lee Pharmaceuticals Europe GmbH, Eli Lilly Nederland B.V., Sanofi Winthrop Industrie
TOTAL APPLICATIONS
8
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
ADMELOGBLA209196SANOFI-AVENTIS USPrescription
ADMELOG SOLOSTARBLA209196SANOFI-AVENTIS USPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
BysumlogGan & Lee Pharmaceuticals Europe GmbHOpinionDiabetes Mellitus
Insulin lispro SanofiSanofi Winthrop IndustrieAuthorised19/07/2017Diabetes Mellitus
Lyumjev (previously Liumjev)Eli Lilly Nederland B.V.Authorised24/03/2020Diabetes Mellitus
LiprologEli Lilly Nederland B.V.Authorised01/08/2001Diabetes Mellitus
HumalogEli Lilly Nederland B.V.Authorised30/04/1996Diabetes Mellitus
LiprologEli Lilly and Company LimitedWithdrawn07/05/1997Diabetes Mellitus

FULL INTELLIGENCE ON INSULIN LISPRO

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →